-
Doxorubicin: Applied Protocols and Resistance Insights for O
2026-05-25
Leverage Doxorubicin’s mechanistic power for cancer research and multidrug resistance modeling. This guide delivers actionable workflows, advanced troubleshooting, and translational strategies grounded in the latest evidence and APExBIO’s experimental reliability.
-
U-73122: Potent Phospholipase C Inhibitor for Cell Signaling
2026-05-25
U-73122 is a selective phospholipase C inhibitor that disrupts PLC-β2-mediated signal transduction. It modulates calcium flux and chemotaxis, crucial in apoptosis and inflammation research. Robust evidence supports its use in dissecting PLC signaling pathways in cancer and immune cell models.
-
Azathramycin A: Strategic Leverage in TB Macrolide Research
2026-05-24
This article explores Azathramycin A as a precision tool for translational tuberculosis research, blending mechanistic insights, experimental best practices, and competitive context. Building on macrolide pharmacodynamics and recent advances, it provides actionable guidance for researchers seeking robust models of protein synthesis inhibition and antibiotic resistance.
-
Dibutyryl-cAMP, Sodium Salt: Accelerating cAMP Pathway Resea
2026-05-23
Dibutyryl-cAMP, sodium salt (DBcAMP sodium salt) empowers researchers to dissect and modulate cAMP signaling with unmatched precision. APExBIO’s high-purity, cell-permeable cAMP analog is the tool of choice for robust pathway activation, troubleshooting, and advanced model systems—from neuronal slice cultures to inflammation studies.
-
Multiomics Dissects Drug Mechanisms in Acute Liver Injury Mo
2026-05-22
This study applies a multiomics framework to elucidate how bifendate and muaddil sapra modulate gene and protein networks in acute liver injury. By integrating transcriptomic and proteomic analyses, the research identifies key regulatory modules and highlights the drugs’ distinct molecular actions, offering a template for targeted therapy development.
-
Fucoidan: Protocol Advances for Anticancer Polysaccharide Re
2026-05-22
APExBIO's Fucoidan enables robust, targeted workflows for oncology and immunology research, offering protocol flexibility and unparalleled purity. This guide translates new mechanistic insights into hands-on experimental advantages and troubleshooting strategies.
-
DiscoveryProbe Bioactive Compound Library Plus: Workflows &
2026-05-21
The DiscoveryProbe™ Bioactive Compound Library Plus (SKU: L1022P) empowers high-throughput screening and advanced pathway analysis with 5,072 rigorously validated bioactive compounds. This article details optimized workflows, troubleshooting strategies, and experimental enhancements that set this APExBIO library apart for drug discovery and mechanism-of-action studies.
-
DPP9-KEAP1 Complex: Redox Sensing and Inflammasome Regulatio
2026-05-21
This study uncovers a mutually inhibitory interaction between the serine protease DPP9 and the redox sensor KEAP1, directly linking inflammasome regulation to cellular redox homeostasis. The findings provide a new conceptual framework for understanding how redox signals and protease activity converge to modulate innate immune responses, with implications for mitochondrial dysfunction and neurodegenerative disease research.
-
CPI-613 in Tumor Cell Metabolism: Protocols and Optimization
2026-05-20
CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) offers a targeted, reproducible approach for dissecting mitochondrial metabolism and apoptosis in cancer research models. Discover how strategic integration of CPI-613, backed by recent mechanistic studies, streamlines tumor cell assays and advances acute myeloid leukemia and NSCLC workflows.
-
Cell Counting Kit-8 (CCK-8) Plus: Enhanced Tetrazolium Salt
2026-05-20
The Cell Counting Kit-8 (CCK-8) Plus provides rapid and sensitive quantification of living cells, enabling reliable cell proliferation and cytotoxicity assays. It is best suited for in vitro applications requiring precise dehydrogenase activity measurement, but should not be used where endpoint cell lysis or redox interference is unavoidable.
-
Toxicity of Sulfamonomethoxine in Aquatic Organisms: Insight
2026-05-19
This study systematically quantifies the acute and chronic toxicity of the sulfonamide antibiotic sulfamonomethoxine (SMM) across five aquatic species, revealing pronounced sensitivity in microalgae compared to cladocerans and fish. The findings highlight the ecological risks posed by SMM residues in aquatic environments and offer a robust foundation for environmental hazard assessment and buffer optimization in aquatic toxicity assays.
-
Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding
2026-05-19
A recent study reveals that naturally occurring angiotensin peptides, including Angiotensin III, significantly enhance binding of the SARS-CoV-2 spike protein to the host AXL receptor. This work provides mechanistic insight into potential links between the renin–angiotensin–aldosterone system (RAAS) and COVID-19 pathogenesis, with implications for both cardiovascular and infectious disease research.
-
Fucoidan Downregulates Caveolin-1 in MCF-7 Breast Cancer Cel
2026-05-18
This study demonstrates that fucoidan—a sulfated α-L-fucan from brown algae—selectively reduces caveolin-1 expression in MCF-7 breast cancer cells, revealing a novel mechanism for its antitumor activity. The findings suggest caveolin-1 modulation as a promising therapeutic strategy and provide new impetus for translational research on anticancer polysaccharides.
-
Oseltamivir Acid: Influenza Neuraminidase Inhibitor Benchmar
2026-05-18
Oseltamivir acid is a potent influenza neuraminidase inhibitor and active metabolite of oseltamivir phosphate. It directly inhibits viral sialidase activity, interrupting influenza virus replication and spread. Research demonstrates robust in vitro and in vivo efficacy, but resistance via H275Y mutation is a significant limitation.
-
ATM Inhibition with Fenofibrate: Synergy in Ovarian Cancer C
2026-05-17
This study demonstrates that ATM kinase inhibition synergizes with the metabolic drug fenofibrate to induce senescence in high grade serous ovarian cancer (HGSOC) cells. The findings highlight a new combinatorial approach for treating HR-proficient HGSOC, which is often resistant to current therapies.